Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acusphere Inc. stock logo
ACUS
Acusphere
$0.00
$0.00
$0.00
N/A-1.87N/AN/A
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
$0.99
$0.99
$0.99
$0.99
N/A0.25N/AN/A
Hypermarcas stock logo
HYPMY
Hypermarcas
$4.79
+1.0%
$4.67
$2.64
$5.92
$3.00B0.81264,639 shs229,224 shs
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
$0.03
$0.03
$0.01
$0.04
$11.28M-1.184,445 shsN/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acusphere Inc. stock logo
ACUS
Acusphere
0.00%0.00%0.00%0.00%+900.00%
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
0.00%0.00%0.00%0.00%0.00%
Hypermarcas stock logo
HYPMY
Hypermarcas
-1.71%-0.68%-2.32%+36.67%-5.15%
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
0.00%0.00%0.00%0.00%+180.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acusphere Inc. stock logo
ACUS
Acusphere
N/AN/AN/AN/AN/AN/AN/AN/A
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Hypermarcas stock logo
HYPMY
Hypermarcas
N/AN/AN/AN/AN/AN/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acusphere Inc. stock logo
ACUS
Acusphere
0.00
N/AN/AN/A
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
0.00
N/AN/AN/A
Hypermarcas stock logo
HYPMY
Hypermarcas
4.00
Strong BuyN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest HYPMY, NEVPF, ACUS, and ADDXF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2025
Hypermarcas stock logo
HYPMY
Hypermarcas
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acusphere Inc. stock logo
ACUS
Acusphere
N/AN/AN/AN/AN/AN/A
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/AN/AN/A
Hypermarcas stock logo
HYPMY
Hypermarcas
$1.38B2.20$0.48 per share10.04$3.54 per share1.35
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
$10K1,128.43N/AN/A$0.02 per share1.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acusphere Inc. stock logo
ACUS
Acusphere
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/A
Hypermarcas stock logo
HYPMY
Hypermarcas
$248.62M$0.2419.96N/A12.51%6.95%3.34%7/23/2025 (Estimated)
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
-$9.01MN/A0.00N/AN/A-117.92%-102.44%N/A

Latest HYPMY, NEVPF, ACUS, and ADDXF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/23/2025Q1 2025
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A-$0.04N/A-$0.04N/A$184.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acusphere Inc. stock logo
ACUS
Acusphere
N/AN/AN/AN/AN/A
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/AN/A
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.142.92%N/A58.33%N/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/AN/A

Latest HYPMY, NEVPF, ACUS, and ADDXF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.03452.81%6/30/20257/1/20251/8/2027
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acusphere Inc. stock logo
ACUS
Acusphere
N/AN/AN/A
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/A
Hypermarcas stock logo
HYPMY
Hypermarcas
0.63
1.26
0.80
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/A
7.99
7.99

Institutional Ownership

CompanyInstitutional Ownership
Acusphere Inc. stock logo
ACUS
Acusphere
N/A
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/A
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/A

Insider Ownership

CompanyInsider Ownership
Acusphere Inc. stock logo
ACUS
Acusphere
4.60%
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/A
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Acusphere Inc. stock logo
ACUS
Acusphere
118N/AN/ANot Optionable
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
26N/AN/ANot Optionable
Hypermarcas stock logo
HYPMY
Hypermarcas
10,481633.42 millionN/ANot Optionable
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
8403.01 millionN/ANot Optionable

Recent News About These Companies

Pharming announces public cash offer to shareholders of Abliva AB
Stillfront Group publ AB (SFRG)
Probi AB
IVSXF Investor AB (publ)
Interfox Resources publ AB (IFOX)
Cell Impact publ AB (CELLI)
Abliva AB (publ) (NEVPF)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acusphere stock logo

Acusphere OTCMKTS:ACUS

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.

Addex Therapeutics stock logo

Addex Therapeutics OTCMKTS:ADDXF

$0.99 0.00 (0.00%)
As of 02/3/2023

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Hypermarcas stock logo

Hypermarcas OTCMKTS:HYPMY

$4.79 +0.05 (+1.00%)
As of 03:58 PM Eastern

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

Abliva AB (publ) stock logo

Abliva AB (publ) OTCMKTS:NEVPF

$0.03 0.00 (0.00%)
As of 07/21/2025

Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.